19 results on '"Lalu, Manoj M."'
Search Results
2. Sex-based analysis of treatment responses in animal models of sepsis: a preclinical systematic review protocol
- Author
-
Zhang, MengQi, Fergusson, Dean A., Sharma, Rahul, Khoo, Ciel, Mendelson, Asher A., McDonald, Braedon, Macala, Kimberly F., Sharma, Neha, Gill, Sean E., Fiest, Kirsten M., Lehmann, Christian, Shorr, Risa, Jahandideh, Forough, Bourque, Stephane L., Liaw, Patricia C., Fox-Robichaud, Alison, and Lalu, Manoj M.
- Published
- 2023
- Full Text
- View/download PDF
3. Mesenchymal Stromal Cell‐derived Extracellular Vesicles in Preclinical Animal Models of Tumor Growth: Systematic Review and Meta‐analysis
- Author
-
Bailey, Adrian J.M., Tieu, Alvin, Gupta, Manika, Slobodian, Mitchell, Shorr, Risa, Ramsay, Tim, Rodriguez, Rosendo A., Fergusson, Dean A., Lalu, Manoj M., and Allan, David S.
- Published
- 2022
- Full Text
- View/download PDF
4. Neuroprotection by Remote Ischemic Conditioning in Rodent Models of Focal Ischemia: a Systematic Review and Meta-Analysis
- Author
-
Ripley, Allyson J., Jeffers, Matthew S., McDonald, Matthew W., Montroy, Joshua, Dykes, Angela, Fergusson, Dean A., Silasi, Gergely, Lalu, Manoj M., and Corbett, Dale
- Published
- 2021
- Full Text
- View/download PDF
5. Preclinical Studies of MSC-Derived Extracellular Vesicles to Treat or Prevent Graft Versus Host Disease: a Systematic Review of the Literature
- Author
-
Gupta, Manika, Tieu, Alvin, Slobodian, Mitchell, Shorr, Risa, Burger, Dylan, Lalu, Manoj M., and Allan, David S.
- Published
- 2021
- Full Text
- View/download PDF
6. From the Lab to Patients: a Systematic Review and Meta-Analysis of Mesenchymal Stem Cell Therapy for Stroke
- Author
-
Lalu, Manoj M., Montroy, Joshua, Dowlatshahi, Dar, Hutton, Brian, Juneau, Pascale, Wesch, Neil, Y. Zhang, Sarah, McGinn, Ryan, Corbett, Dale, Stewart, Duncan J., and A. Fergusson, Dean
- Published
- 2020
- Full Text
- View/download PDF
7. The effects of resistant starches on inflammatory bowel disease in preclinical and clinical settings: a systematic review and meta-analysis
- Author
-
Montroy, Joshua, Berjawi, Rania, Lalu, Manoj M., Podolsky, Eyal, Peixoto, Cayden, Sahin, Levent, Stintzi, Alain, Mack, David, and Fergusson, Dean A.
- Published
- 2020
- Full Text
- View/download PDF
8. Checklists to detect potential predatory biomedical journals: a systematic review
- Author
-
Cukier, Samantha, Helal, Lucas, Rice, Danielle B., Pupkaite, Justina, Ahmadzai, Nadera, Wilson, Mitchell, Skidmore, Becky, Lalu, Manoj M., and Moher, David
- Published
- 2020
- Full Text
- View/download PDF
9. A primer on systematic reviews in toxicology
- Author
-
Hoffmann, Sebastian, de Vries, Rob B. M., Stephens, Martin L., Beck, Nancy B., Dirven, Hubert A. A. M., Fowle, III, John R., Goodman, Julie E., Hartung, Thomas, Kimber, Ian, Lalu, Manoj M., Thayer, Kristina, Whaley, Paul, Wikoff, Daniele, and Tsaioun, Katya
- Published
- 2017
- Full Text
- View/download PDF
10. Mesenchymal stromal cell extracellular vesicles as therapy for acute and chronic respiratory diseases: A meta‐analysis.
- Author
-
Tieu, Alvin, Hu, Kevin, Gnyra, Catherine, Montroy, Joshua, Fergusson, Dean A., Allan, David S., Stewart, Duncan J., Thébaud, Bernard, and Lalu, Manoj M.
- Subjects
EXTRACELLULAR vesicles ,STROMAL cells ,RESPIRATORY diseases ,PULMONARY arterial hypertension ,CHRONIC diseases ,LUNGS - Abstract
Preclinical studies suggest mesenchymal stromal cell extracellular vesicles (MSC‐EVs) reduce inflammation and improve organ function in lung diseases; however, an objective analysis of all available data is needed prior to translation. Using rigorous meta‐research methods, we determined the effectiveness of MSC‐EVs for preclinical respiratory diseases and identified experimental conditions that may further refine this therapy. A systematic search of MEDLINE/Embase identified 1167 records. After screening, 52 articles were included for data extraction and evaluated for risk of bias and quality of reporting in study design. A random effects meta‐analysis was conducted for acute lung injury (ALI; N = 23), bronchopulmonary dysplasia (BPD; N = 8) and pulmonary arterial hypertension (PAH; N = 7). Subgroup analyses identified EV methods/characteristics that may be associated with improved efficacy. Data is presented as standardized mean differences (SMD) or risk ratios (RR) with 95% confidence intervals (CI). For ALI, MSC‐EVs markedly reduced lung injury (SMD ‐4.33, CI ‐5.73 to ‐2.92), vascular permeability (SMD ‐2.43, CI ‐3.05 to ‐1.82), and mortality (RR 0.39, CI 0.22 to 0.68). Small EVs were more consistently effective than large EVs whereas no differences were observed between tissue sources, immunocompatibility or isolation techniques. For BPD, alveolarization was improved by MSC‐EVs (SMD ‐1.45, CI ‐2.08 to ‐0.82) with small EVs more consistently beneficial then small/large EVs. In PAH, right ventricular systolic pressure (SMD ‐4.16, CI ‐5.68 to ‐2.64) and hypertrophy (SMD ‐2.80, CI ‐3.68 to ‐1.91) were significantly attenuated by EVs. In BPD and PAH, EVs isolated by ultracentrifugation demonstrated therapeutic benefit whereas tangential flow filtration (N = 2) displayed minimal efficacy. Lastly, risk of bias and quality of reporting for experimental design were consistently unclear across all studies. Our findings demonstrate clear potential of MSC‐EVs to be developed as therapy for acute and chronic lung diseases. However, greater transparency in research design and direct comparisons of isolation technique and EV subtypes are needed to generate robust evidence to guide clinical translation. Protocol Registration: PROSPERO CRD42020145334 [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Safety and efficacy of autologous whole cell vaccines in hematologic malignancies: A systematic review and meta‐analysis.
- Author
-
Bastin, Donald J., Khan, Sarwat T., Montroy, Joshua, Kennedy, Michael A., Forbes, Nicole, Martel, Andre B, Baker, Laura, Gresham, Louise, Boucher, Dominique M., Wong, Boaz, Shorr, Risa, Diallo, Jean‐Simon, Fergusson, Dean A., Lalu, Manoj M., Auer, Rebecca C., and Kekre, Natasha
- Subjects
HEMATOLOGIC malignancies ,OVERALL survival ,SURVIVAL rate ,CANCER vaccines ,VACCINE manufacturing - Abstract
Autologous cell vaccines use a patient's tumor cells to stimulate a broad antitumor response in vivo. This approach shows promise for treating hematologic cancers in early phase clinical trials, but overall safety and efficacy remain poorly described. We conducted a systematic review assessing the use of autologous cell vaccination in treating hematologic cancers. Primary outcomes of interest were safety and clinical response, with secondary outcomes including survival, relapse rate, correlative immune assays and health‐quality related metrics. We performed a search of MEDLINE, Embase and the Cochrane Register of Controlled Trials including any interventional trial employing an autologous, whole cell product in any hematologic malignancy. Risk of bias was assessed using a modified Institute of Health Economics tool. Across 20 single arm studies, only 341 of 592 enrolled participants received one or more vaccinations. Primary reasons for not receiving vaccination included rapid disease progression/death and manufacturing challenges. Overall, few high‐grade adverse events were observed. One death was reported and attributed to a GM‐CSF producing allogeneic cell line co‐administered with the autologous vaccine. Of 58 evaluable patients, the complete response rate was 21.0% [95% CI, 10.4%‐37.8%)] and overall response rate was 35.8% (95% CI, 24.4%–49.0%). Of 97 evaluable patients for survival, the 5‐years overall survival rate was 64.9% (95% CI, 52.6%–77.2%) and disease‐free survival was 59.7% (95% CI, 47.7%–71.7%). We conclude that, in hematologic malignancies, based on limited available data, autologous cell vaccines are safe and display a trend towards efficacy but that challenges exist in vaccine manufacture and administration. Key points: Autologous whole cell cancer vaccines appear to be safe for the treatment of hematologic malignancies.Heterogeneity of the limited number of early phase clinical studies limited the ability to determine efficacy of these vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
12. A Scoping Review of Registered Clinical Trials of Convalescent Plasma for COVID-19 and a Framework for Accelerated Synthesis of Trial Evidence (FAST Evidence).
- Author
-
Zheng, Katina, Liao, Gary, Lalu, Manoj M., Tinmouth, Alan, Fergusson, Dean A., and Allan, David S.
- Abstract
Many parallel studies of convalescent plasma with modest enrolment projections have been launched for the treatment of COVID-19. By pooling data from multiple parallel studies that are similar, we can increase the effective sample size and achieve enough statistical power to determine effectiveness more quickly through meta-analysis. A scoping review of registered clinical trials of convalescent plasma for COVID-19 was conducted to assess the feasibility of performing a rapid and timely meta-analysis that will support accelerated review for approval and implementation. ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform were searched April 23, 2020. Trials were included if they utilized convalescent plasma to treat or prevent COVID-19. Forty-eight registered trials (projected to enroll more than 5000 subjects) of convalescent plasma were identified and included for analysis. The majority of studies (33 studies with 4440 projected enrolment) will address the treatment of severe and/or critical cases of COVID-19. Twenty-nine studies are controlled and 17 of these are reported as actively recruiting. The combined enrolment of patients from similar studies should be sufficient to determine meaningful improvements in mortality, rates of admission to intensive care and need for mechanical ventilation by the end of 2020—sooner than any individual study could determine effectiveness. Accessing supplemental outcome data from investigators may be needed; however, to align reporting of some outcomes from these studies. Heterogeneity in product potency due to different antibody titers is anticipated and studies using conventional treatment as controls instead of placebo may complicate our understanding of efficacy. Convalescent plasma is being tested in ongoing controlled studies, largely to treat severe and/or critical cases of COVID-19. Sufficient combined power to detect clinically important reductions in multiple outcomes, including mortality, is expected by September 2020. Regulatory approval, funding and implementation by blood operators could be accelerated by planned meta-analysis as study results become available. • Effective therapies are lacking for severe and critical COVID-19. • Many trials of convalescent plasma for COVID-19 are expected to be completed in 2020. • Rapid meta-analysis of placebo-controlled RCTs using convalescent plasma can assess efficacy. • This framework for accelerated evidence synthesis can accelerate treatment approval. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
13. A Scoping Review of Registered Clinical Trials of Cellular Therapy for COVID-19 and a Framework for Accelerated Synthesis of Trial Evidence—FAST Evidence.
- Author
-
Liao, Gary, Zheng, Katina, Lalu, Manoj M., Fergusson, Dean A., and Allan, David S.
- Abstract
The urgent need for safe and effective treatments for COVID-19 has fueled the launch of many parallel complex studies of cellular therapies with small to modest enrolment projections. By pooling data from multiple studies that are similar, we can increase the ability to achieve sufficient power to determine effectiveness more quickly through meta-analysis. A scoping review of registered clinical trials using cell-based interventions for COVID-19 was conducted to identify candidate studies for meta-analysis that could support an accelerated regulatory review. ClinicalTrials.gov and WHO International Clinical Trials Registry Platform were searched April 23, 2020. Trials were included if they utilized cell or cell-derived products to treat or prevent COVID-19. Fifty-four registered cellular therapy trials were identified and included for analysis. Studies of mesenchymal stromal cells (MSCs; 41 studies; 1129 subjects projected to receive cells) and natural killer (NK) cells (5 studies; 135 projected to received cells) were observed most commonly. A subset of studies are controlled (34 studies, or 63%), including 27 studies of MSCs and 3 of NK cells. While heterogeneity in study design exists, the cumulative projected enrolment of patients from similar studies appears sufficient to allow the detection of meaningful differences in clinically important outcomes such as mortality, admission to intensive care and need for mechanical ventilation by September 2020—sooner than any individual study could determine effectiveness. MSCs are the predominant cell type in registered trials for severe or critical COVID-19 and represent the most promising candidates for future meta-analysis. Sufficient pooled sample size to detect clinically important reductions in multiple outcomes, including mortality, is anticipated by September 2020, but may require accessing supplementary data to align outcome reporting. Regulatory approval, funding and implementation by cell manufacturing partners will be accelerated by our framework for rapid meta-analysis. • Effective therapies are lacking for severe and critical COVID-19. • Many registered cell-based clinical trials are expected to be completed in 2020. • Pooling of data from similar controlled trials in real-time meta-analysis is feasible. • A framework for accelerated evidence synthesis could expedite treatment approval. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
14. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
- Author
-
Grigor, Emma J.M., Fergusson, Dean, Kekre, Natasha, Montroy, Joshua, Atkins, Harold, Seftel, Matthew D., Daugaard, Mads, Presseau, Justin, Thavorn, Kednapa, Hutton, Brian, Holt, Robert A., and Lalu, Manoj M.
- Abstract
Promising efficacy results of chimeric antigen receptor (CAR) T-cell therapy have been tempered by safety considerations. Our objective was to comprehensively summarize the efficacy and safety of CAR-T cell therapy in patients with relapsed or refractory hematologic or solid malignancies. MEDLINE, Embase, and the Cochrane Register of Controlled Trials (inception – November 21, 2017). Interventional studies investigating CAR-T cell therapy in patients with malignancies were included. Our primary outcome of interest was complete response (defined as the absence of detectable cancer). Two independent reviewers extracted relevant data, assessed risk of bias, and graded the quality of evidence using established methods. A total of 42 hematological malignancy studies and 18 solid tumor studies met were included (913 participants). Of 486 evaluable hematologic patients, 54.4% [95% CI, 42.5%-65.9%] experienced complete response in 27 CD19 CAR-T cell therapy studies. Of 65 evaluable hematologic patients, 24.4% [95% CI, 9.4%-50.3%] experienced complete response in seven non-CD19 CAR-T cell therapy studies. Cytokine release syndrome was experienced by 55.3% [95% CI, 40.3%-69.4%] of patients and neurotoxicity 37.2% [95% CI, 28.6%-46.8%] of patients with hematologic malignancies. Of 86 evaluable solid tumor patients, 4.1% [95% CI, 1.6%-10.6%] experienced complete response in eight CAR-T cell therapy studies. Limitations include heterogeneity of study populations, as well as high risk of bias of included studies. There was a strong signal for efficacy of CAR-T cell therapy in patients with CD19+ hematologic malignancies and no overall signal in solid tumor trials published to date. These results will help inform patients, physicians, and other stakeholders of the benefits and risks associated with CAR-T cell therapy. • CAR-T cell therapy is most effective in DLBCL and CD19-positive ALL patients. • There is limited evidence of efficacy of CAR-T cell therapy in solid malignancies. • This study provides a comprehensive summary of the efficacy CAR-T cell therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
15. Acquired Factor XIII Inhibitor in Hospitalized and Perioperative Patients: A Systematic Review of Case Reports and Case Series.
- Author
-
Tone, Kira J., James, Tyler E., Fergusson, Dean A., Tinmouth, Alan, Tay, Jason, Avey, Marc T., Kilty, Shaun, and Lalu, Manoj M.
- Abstract
Factor XIII (FXIII) cross-links fibrin monomers to support clot stabilization and wound healing. Acquired FXIII deficiency is caused by autoantibodies that inhibit FXIII and can result in bleeding despite normal routine coagulation test results. Given the rarity of this disease, large clinical studies are not feasible. We therefore conducted a systematic review of case reports and case series of acquired FXIII inhibitor to evaluate potential management and treatment strategies for acquired FXIII inhibitor in hospitalized and/or perioperative patients. A systematic search of MEDLINE, Embase, and Web of Science identified reports of hospitalized and perioperative patients with acquired FXIII deficiency. No restrictions were placed on language or publication type. Article screening and data extraction were performed independently by 2 abstractors. Completeness of reporting was evaluated according to modified elements from the CAse REport (CARE) guidelines. A total of 1028 citations were reviewed, with 36 case reports and 3 case series meeting eligibility criteria (63 patients total). The mean age was 60 (range, 9-87) years with balanced sex representation. At presentation, 48 patients (76%) had intramuscular or subcutaneous bleeding, and 34 patients (54%) had external or surgical bleeding. All cases were diagnosed by initially detecting a FXIII deficiency and then identifying the inhibitor. Clinical improvement in bleeding was seen in patients receiving FXIII concentrate (13/17 patients), cryoprecipitate (5/8), and plasma (10/18). Inhibitor reduction was seen in patients who received rituximab (6/6 patients), plasma exchange (2/2), intravenous immunoglobulin (4/5), steroid (15/20), and cyclophosphamide (10/15). Concurrent initiation of multiple therapies and obvious lack of control comparisons made direct association to outcomes difficult to establish. Outcomes were reported for 55 patients, with 25 patients (45%) having complete inhibitor eradication and 15 patients (27%) having partial resolution; 9 of these patients (14%) had a relapse. Thirteen patients (20%) died (7 from internal hemorrhage). Completeness of reporting varied for specific CAse REport items. Patient demographics, clinician-assessed outcomes, and laboratory test results were reported in all case reports. Least reported items included informed consent (6%), patient perspective (3%), and a title containing the words case report (9%). Our systematic review provides the most complete overview of published reports of FXIII acquired inhibitor to date. There is a paucity of data available on FXIII acquired inhibitor, and the available data may be limited by variable reporting. Despite multimodal therapy, a significant proportion of patients with FXIII acquired inhibitor have a large burden of morbidity and mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
16. Efficacy and safety of regenerative cell therapy for pulmonary arterial hypertension in animal models: a preclinical systematic review protocol.
- Author
-
Suen, Colin M., Zhai, Alex, Lalu, Manoj M., Welsh, Christopher, Levac, Brendan M., Fergusson, Dean, McIntyre, Lauralyn, and Stewart, Duncan J.
- Subjects
CELLULAR therapy ,PULMONARY hypertension treatment - Abstract
Background: Pulmonary arterial hypertension (PAH) is a rare disease (15 cases per million) that is characterized by widespread loss of the pulmonary microcirculation and elevated pulmonary vascular resistance leading to pathological right ventricular remodeling and ultimately right heart failure. Regenerative cell therapies (i.e., therapies involving cells with stem or progenitor-like properties) could potentially restore the effective lung microcirculation and provide a curative therapy for PAH. Preclinical evidence suggests that regenerative cell therapy using endothelial progenitor cells or mesenchymal stem cells may be beneficial in the treatment of PAH. These findings have led to the completion of a small number of human clinical trials, albeit with modest effect compared to animal studies. The objective of this systematic review is to compare the efficacy and safety of regenerative cell therapies in preclinical models of PAH as well as assess study quality to inform future clinical studies. Methods: We will include preclinical studies of PAH in which a regenerative cell type was administered and outcomes compared to a disease control. The primary outcome will be pulmonary hemodynamics as assessed by measurement of right ventricular systolic pressure and/or mean pulmonary arterial pressure. Secondary outcomes will include mortality, survival, right ventricular remodeling, pulmonary vascular resistance, cardiac output, cardiac index, pulmonary acceleration time, tricuspid annular systolic excursion, and right ventricular wall thickness. Electronic searches of MEDLINE and EMBASE databases will be constructed and reviewed by the Peer Review of Electronic Search Strategies (PRESS) process. Search results will be screened independently in duplicate. Data from eligible studies will be extracted, pooled, and analyzed using random effects models. Risk of bias will be assessed using the SYstematic Review Centre for Laboratory animal Experimentation (SYRCLE) risk of bias tool, and individual study reporting will be assessed according to an itemized checklist based on the Animal Research: Reporting of In vivo Experiments (ARRIVE) guidelines. Discussion: This systematic review will examine the efficacy and safety of regenerative cell therapy in preclinical models of PAH. As well, the literature will be assessed for study quality and risk of bias. The results will guide the design of future clinical trials and preclinical animal studies. Systematic review registration: CAMARADES (http://www.dcn.ed.ac.uk/camarades/SyRF/Protocols.htm). [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
17. Ultrasound-Guided Subclavian Vein Catheterization: A Systematic Review and Meta-Analysis.
- Author
-
Lalu, Manoj M., Fayad, Ashraf, Ahmed, Osman, Bryson, Gregory L., Fergusson, Dean A., Barron, Carly C., Sullivan, Patrick, and Thompson, Calvin
- Subjects
- *
SUBCLAVIAN veins , *ARTERIAL catheterization , *ULTRASONIC imaging , *RANDOM effects model , *PNEUMOTHORAX , *DATA extraction , *HEMATOMA , *SURGERY - Abstract
Objective: Although ultrasound guidance for subclavian vein catheterization has been well described, evidence for its use has not been comprehensively appraised. Thus, we conducted a systematic review and meta-analysis to determine whether ultrasound guidance of subclavian vein catheterization reduces catheterization failures and adverse events compared to the traditional "blind" landmark method. All forms of ultrasound were included (dynamic 2D ultrasound, static 2D ultrasound, and Doppler). Data Sources: Medline, Embase, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and CINAHL (from inception to September 2014).Study Selection: Randomized controlled trials of ultrasound compared to landmark technique for subclavian catheterization in adult populations were considered. Outcomes of interest included safety and failure of catheterization. Data Extraction: Adverse event data were analyzed according to Peto's method and expressed as odd ratios and 95% CIs. Failure of catheterization was analyzed with inverse variance random effects modeling and expressed as risk ratios and 95% CI. Data Synthesis: Six hundred and one studies were reviewed and 10 met inclusion criteria (n = 2,168 participants). Six used dynamic 2D ultrasound (n = 719), one used static 2D ultrasound (n = 821), and three used Doppler-guided insertion techniques (n = 628). Overall complication rates were reduced with ultrasound use compared to the landmark group (odd ratio, 0.53; 95% CI, 0.41-0.69). Subgroup analysis demonstrated that dynamic 2D ultrasound reduced inadvertent arterial puncture, pneumothorax, and hematoma formation. No difference in failure of catheterization was noted between the ultrasound group and the landmark method (risk ratio, 0.85; 95% CI, 0.48-1.51). Subgroup analysis of dynamic 2D ultrasound demonstrated a significant decrease in failed catheterization (risk ratio, 0.24; 95% CI, 0.06-0.92). Conclusions: Ultrasound-guided subclavian catheterization reduced the frequency of adverse events compared with the landmark technique. Our findings support the use of dynamic 2D ultrasound for subclavian catheterization to reduce adverse events and failed catheterization. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
18. A declaração PRISMA 2020: diretriz atualizada para relatar revisões sistemáticas.
- Author
-
Page, Matthew J., McKenzie, Joanne E., Bossuyt, Patrick M., Boutron, Isabelle, Hoffmann, Tammy C., Mulrow, Cynthia D., Shamseer, Larissa, Tetzlaff, Jennifer M., Akl, Elie A., Brennan, Sue E., Chou, Roger, Glanville, Julie, Grimshaw, Jeremy M., Hróbjartsson, Asbjørn, Lalu, Manoj M., Tianjing Li, Loder, Elizabeth W., Mayo-Wilson, Evan, McDonald, Steve, and McGuinness, Luke A.
- Subjects
- *
REPORT writing , *SYSTEMATIC reviews , *RESEARCH methodology , *TERMS & phrases , *AUTHORSHIP - Abstract
The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement, published in 2009, was designed to help systematic reviewers transparently report why the review was done, what the authors did, and what they found. Over the past decade, advances in systematic review methodology and terminology have necessitated an update to the guideline. The PRISMA 2020 statement replaces the 2009 statement and includes new reporting guidance that reflects advances in methods to identify, select, appraise, and synthesise studies. The structure and presentation of the items have been modified to facilitate implementation. In this article, we present the PRISMA 2020 27-item checklist, an expanded checklist that details reporting recommendations for each item, the PRISMA 2020 abstract checklist, and the revised flow diagrams for original and updated reviews. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
19. A systematic review on the efficacy and safety of low molecular weight heparin as an anticancer therapeutic in preclinical animal models.
- Author
-
Ripsman, David, Fergusson, Dean A., Montroy, Joshua, Auer, Rebecca C., Huang, Johnny W., Dobriyal, Aditi, Wesch, Neil, Carrier, Marc, and Lalu, Manoj M.
- Subjects
- *
ANIMAL models in research , *MOLECULAR weights , *TREATMENT effectiveness , *LUNG cancer , *PLACEBOS - Abstract
The therapeutic effects of low molecular weight heparins (LMWH) may extend past thrombosis prevention, with preclinical evidence demonstrating anti-metastatic properties. Clinical evidence on the topic, however, remains controversial. A systematic review of preclinical evidence may help elucidate reasons for this contradictory evidence. The objective of our systematic review is to assess the anti-metastatic properties of LMWHs in solid tumour animal models. MEDLINE, Embase, Web of Science and PubMed were searched from inception to May 12th, 2020. All articles were screened independently and in duplicate. Studies that compared LMWH to a placebo or no treatment arm in solid tumour animal models were included. The primary outcome was the burden of metastasis. Secondary outcomes included primary tumour growth and mortality. The risk of bias was assessed in duplicate using a modified Cochrane Risk of Bias tool. Forty-two studies were included in the review. Administration of a LMWH was associated with a significant decrease in the burden of metastasis (SMD −2.18; 95% CI −2.66 to −1.70). Additionally, the administration of a LMWH was also associated with a significant reduction in primary tumour growth (SMD −1.95; 95% CI −2.56 to −1.34) and risk of death (RR 0.39; 95% CI 0.16–0.97). All included studies were deemed to be at an unclear risk of bias for at least one methodological criterion. Our results demonstrate that LMWH can effectively reduce metastatic burden and reduce tumour growth in preclinical animal models of solid tumour malignancies. Reasons for the contradiction with clinical evidence require further exploration. • 42 studies of anti-metastatic effects of LMWHs in solid malignancy animal models • LMWHs reduce metastases, decrease tumour growth and increase survival in animals • Discrepancy between efficacy of LMWHs in animals and failure in clinical trials • Areas with limited preclinical study (i.e. lung cancer) should be explored. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.